A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC. This is an ASCO Meeting Abstract from the 2014 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback